Viewing Study NCT06624020



Ignite Creation Date: 2024-10-26 @ 3:41 PM
Last Modification Date: 2024-10-26 @ 3:41 PM
Study NCT ID: NCT06624020
Status: COMPLETED
Last Update Posted: None
First Post: 2024-09-30

Brief Title: A Study to Learn About How Medicines Called CDK46 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia
Sponsor: None
Organization: None

Study Overview

Official Title: Characteristics and Real-world Use of Palbociclib and Other CDK46is in Naive Patients in Australia a Retrospective Analysis ROSIE
Status: COMPLETED
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ROSIE
Brief Summary: The purpose of this study is to learn about how a class of medicines called CDK46 inhibitors are used for the treatment of breast cancer in patients in Australia The study looks at how the CDK46 inhibitor class of drugs are used for treating breast cancer that is advanced or metastatic has spread to other parts of the body

This study does not include patients Instead this study looks at already available data to describe characteristics like age and sex of patients who have already taken these medicines

This study will focus on one of these medicines called palbociclib and will look at the data to learn what amounts of the study medicine palbociclib patients receive and how long patients take it for in the real-world in Australia This study will also learn what other anti-cancer medicines patients receive including chemotherapy Chemotherapy is the treatment that uses medicines to stop the growth of cancer cells either by killing the cells or by stopping them from dividing
Detailed Description: None

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: